Novo Nordisk Inc. et al v. Hikma Pharmaceuticals USA Inc.
| Novo Nordisk Inc. and Novo Nordisk A/S |
| Hikma Pharmaceuticals USA Inc. |
| 1:2021cv01783 |
| December 21, 2021 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 7, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 42 STIPULATION TO EXTEND TIME to submit the Joint Claim Construction Chart to November 9, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
Filing 41
SO ORDERED, re #40 Joint STIPULATION TO EXTEND TIME OF SUBSTANTIAL COMPLETION OF DOCUMENT PRODUCTION to 01/06/2023, filed by Hikma Pharmaceuticals USA Inc. Signed by Judge Colm F. Connolly on 11/7/2022. (kmd)
|
| Filing 40 Joint STIPULATION TO EXTEND TIME OF SUBSTANTIAL COMPLETION OF DOCUMENT PRODUCTION to 01/06/2023 - filed by Hikma Pharmaceuticals USA Inc.. (Lennon, James) |
| Filing 39 NOTICE OF SERVICE of Plaintiffs' Proposed Claim Terms for Construction filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) |
| Filing 38 NOTICE OF SERVICE of Defendant Hikma Pharmaceuticals USA Inc.'s List of Proposed Claim Terms for Construction filed by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
|
SO ORDERED, re #37 STIPULATION TO EXTEND TIME to submit the Joint Claim Construction Chart to November 7, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 10/28/2022. (kmd)
|
| Filing 37 STIPULATION TO EXTEND TIME to submit the Joint Claim Construction Chart to November 7, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
| Filing 36 NOTICE OF SERVICE of Novo Nordisk's Preliminary Identification of Claim Terms and Phrases for Construction - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) |
| Filing 35 NOTICE OF SERVICE of Defendant Hikma Pharmaceuticals USA Inc.'s List of Proposed Claim Terms for Construction filed by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
| Filing 34 REDACTED VERSION of Notice of Subpoena filed on 9-28-2022 - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
| Filing 33 NOTICE OF SERVICE of Novo Nordisk's Initial Responses to Defendants' Invalidity Contentions Regarding U.S. Patent Nos. 8,114,833 and 9,265,893 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) |
| Filing 32 [SEALED] NOTICE of Subpoena - by Novo Nordisk A/S, Novo Nordisk Inc. (Murray, Travis) |
| Filing 31 NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) |
|
SO ORDERED, re #30 MOTION for Pro Hac Vice Appearance of Attorney Olivia L. Wheeling, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 9/16/2022. (kmd)
|
| Filing 30 MOTION for Pro Hac Vice Appearance of Attorney Olivia L. Wheeling - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
| Filing 29 NOTICE of of Service of (1) Defendant Hikma Pharmaceuticals USA Inc.s Objections and Responses to Plaintiffs Second Set of Requests for the Production of Documents and Things (Nos. 7-84); and (2) Defendant Hikma Pharmaceuticals USA Inc.s Objections and Responses to Plaintiffs First Set of Interrogatories (Nos. 1-14) by Hikma Pharmaceuticals USA Inc. (Lennon, James) |
| Filing 28 NOTICE OF SERVICE of Defendant Hikma Pharmaceuticals USA Inc.'s Initial Non-Infringement Contentions filed by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
| Filing 27 NOTICE OF SERVICE of (1) Plaintiffs' First Set of Interrogatories (Nos. 1-14); and (2) Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 7-84) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) |
| Filing 26 NOTICE OF SERVICE of Defendant Hikma Pharmaceuticals USA Inc.'s Objections and Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-6) filed by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
| Filing 25 NOTICE OF SERVICE of Plaintiffs' Preliminary Disclosure of Asserted Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
| Filing 24 NOTICE OF SERVICE of Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-6) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
|
SO ORDERED, re #23 Stipulation Regarding the Discovery of Electronically Stored Information, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 6/3/2022. (kmd) Modified on 6/3/2022 (kmd).
|
|
SO ORDERED, re #22 Proposed Protective Order, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 6/3/2022. (kmd)
|
| Filing 23 STIPULATION and Proposed Order Regarding the Discovery of Electronically Stored Information by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Filing 22 PROPOSED ORDER -- Protective Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
|
Filing 21
SO ORDERED, re #20 STIPULATION TO EXTEND TIME to submit a proposed order for the discovery of electronically-stored information ("ESI Order") and a proposed Protective Order to June 2, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/25/2022. (kmd)
|
| Filing 20 STIPULATION TO EXTEND TIME to submit a proposed order for the discovery of electronically-stored information ("ESI Order") and a proposed Protective Order to June 2, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Filing 19 NOTICE OF SERVICE of (1) Plaintiffs' Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Plaintiffs' Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
| Filing 18 NOTICE OF SERVICE of (1) Defendant Hikma Pharmaceuticals USA Inc.'s Rule 26(a)(1) Initial Disclosures; and (2) Defendant Hikma Pharmaceuticals USA Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
|
Filing 17
SCHEDULING ORDER: Joinder of Parties due by 2/10/2023. Amended Pleadings due by 2/10/2023. Fact Discovery completed by 3/10/2023. Expert Discovery due by 8/4/2023. Joint Claim Construction Brief due by 1/9/2023. A Markman Hearing is set for 2/7/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 10/31/2023. A Final Pretrial Conference is set for 11/21/2023 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 12/4/2023 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 5/5/2022. (nmf)
|
| Filing 16 PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: #1 Letter to The Honorable Colm F. Connolly)(Egan, Brian) |
| The 5/6/2022 Scheduling Conference is canceled per D.I. #16 . (nmf) |
|
Filing 15
Order Setting Telephonic Scheduling Conference: A Scheduling Conference is set for 5/6/2022 at 08:30 AM Telephonically before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 3/30/2022. (nmf)
|
| Filing 14 Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding coordinated discovery and Markman - re (13 in 1:21-cv-01783-CFC, 13 in 1:21-cv-01783-CFC, 10 in 1:21-cv-01782-CFC, 10 in 1:21-cv-01782-CFC) Order,, Set Deadlines,. (Egan, Brian) |
| Pro Hac Vice Attorney Sharon Lin for Hikma Pharmaceuticals USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) |
|
Filing 13
ORDER: IT IS ORDERED that, on or before March 4, 2022, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated as to the above cases and, if so, when a joint scheduling conference might most efficiently be conducted.ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 3/4/2022.) Signed by Judge Colm F. Connolly on 2/4/2022. Associated Cases: 1:21-cv-01782-CFC, 1:21-cv-01783-CFC(nmf)
|
| Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran and Erica R. Sutter - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) |
|
SO ORDERED, re #12 MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran and Erica R. Sutter, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 2/3/2022. (kmd)
|
| Filing 11 ANSWER to #8 Answer to Complaint, Counterclaim -- Answer to Counterclaims -- by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| Pro Hac Vice Attorney Charles B. Klein for Hikma Pharmaceuticals USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Filing 10 MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein and Sharon Lin - filed by Hikma Pharmaceuticals USA Inc.. (Lennon, James) |
|
SO ORDERED, re #10 MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein and Sharon Lin, filed by Hikma Pharmaceuticals USA Inc. Ordered by Judge Colm F. Connolly on 1/13/2022. (kmd)
|
| Filing 9 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hikma Pharmaceuticals, PLC for Hikma Pharmaceuticals USA Inc. filed by Hikma Pharmaceuticals USA Inc.. (Lennon, James) |
| Filing 8 ANSWER to #1 Complaint, , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Hikma Pharmaceuticals USA Inc..(Lennon, James) |
| Remark: DI 9 re Disclosure Statement removed per Request of Counsel and will be refiled. (twk) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:21-cv-01782-CFC, 1:21-cv-01783-CFC (rjb) |
| Filing 7 SUMMONS Returned Executed by Novo Nordisk Inc., Novo Nordisk A/S. Hikma Pharmaceuticals USA Inc. served on 12/22/2021, answer due 1/12/2022. (Blumenfeld, Jack) |
| Filing 6 Summons Issued with Magistrate Consent Notice attached as to Hikma Pharmaceuticals USA Inc. on 12/22/2021. (mal) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo A/S for Novo Nordisk A/S; Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc.; and Novo Nordisk US Holdings Inc. is a privately held corporation wholly owned by Novo Nordisk A/S. - filed by Novo Nordisk A/S and Novo Nordisk Inc.. (mal) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,579,869 B2 ;7,762,994 B2 ;8,114,833 B2 ;9,265,893 B2. (mal) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/12/2021. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 5/12/2024. (mal) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Filing 1 COMPLAINT filed against Hikma Pharmaceuticals USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3768392.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: #1 Exhibit A-D, #2 Civil Cover Sheet)(mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
